focus -WSS

focus

author：explore 2025-09-06 04:14:46 - browse：6

ASH19 CAR-T — Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： WHO may add ‘noma' to its list of neglected tropical diseases

WSS

Amazon on where the company's health care bets are headed next

Testing for cancer recurrence creates a new limbo for patients

Eli Lilly to pay $200M for Beam’s stake in gene

Chimpanzees, like humans and whales, get menopause: Study

How generative AI is inspiring dreams of a health data revolution

The pink breast cancer awareness ribbon needs a redesign

entertainment

focus

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Physician subsidies by hospitals soar in wake of No Surprises Act

Drug repurposing or repositioning? The language matters

ALS advocates say criticism of new drugs misses bigger picture

Medicare proposal to cover medical devices draws a mixed reaction

Chimpanzees, like humans and whales, get menopause: Study

Guidelines to prevent youth baseball injuries need more muscle

AstraZeneca chief proposes a novel edit to the drug pricing bill

Alkermes shareholders re

Crinetics acromegaly drug succeeds in late

Wikipedia

CDC recommends rationing of RSV shot due to shortages

Diversifying clinical trials isn't enough to close racial gaps: study

House transparency, PBM reform bill gains bipartisan support

Stem cell treatment guidelines are released by FDA

Testing for cancer recurrence creates a new limbo for patients

Cassava reveals details — and problems — with Alzheimer's study

focus

hotspot

hotspot

leisure time